Chulalongkorn University Develops Stem Cell Therapy for Canine…

Event summary

Chulalongkorn University researchers have developed stem cell technology from canine adipose tissue to produce insulin-secreting cells, potentially offering a cure for diabetes in dogs and cats.
The team successfully transformed adipose-derived stem cells into functional beta cells capable of secreting insulin and lowering blood sugar levels in animal models.
The research, led by Assoc. Prof. Chenphop Sawangmake, has demonstrated promising results in animal studies, with plans to begin clinical trials in diabetic dogs within 2-3 years.
The technology leverages adipose tissue due to its ease of collection, safety, and high yield of stem cells, making it accessible for pet owners.
The team is scaling up beta-cell production using microfluidics technology and exploring exosome therapy as a complementary approach.

The big picture

Chulalongkorn University's breakthrough in stem cell therapy for canine diabetes represents a significant advancement in regenerative veterinary medicine. The research not only addresses a critical unmet need in animal health but also has potential applications in human diabetes treatment. The university's focus on translational research and its establishment of a spin-off company highlight its commitment to commercializing innovative technologies. This development underscores the growing intersection between veterinary and human medicine, where insights from animal models can drive therapeutic advancements.

What we're watching

Clinical Translation: The pace at which the therapy transitions from animal models to clinical trials in diabetic dogs will determine its commercial viability.
Regulatory Approval: Whether the therapy can navigate regulatory pathways for veterinary applications and potentially human medicine.
Market Adoption: How pet owners and veterinarians will respond to this innovative treatment, given the current reliance on insulin injections.